Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has told DirectorsTalk it has completed patient enrolment for its Phase IIb dose-finding study, G204, in the
Commenting on the trading update, Manuel Llobet, Chief Executive Officer, said: “We are delivering double digit growth at constant currency and gaining market share despite a flat to low European market.
In this months Hardman & Co report the feature article is “Survey shows underlying strengths in wealth manager business models” By Keith Hiscock, C.E.O. The survey recently published by ComPeer
Panmure Gordon Analyst Dr Mike Mitchell said of Allergy Therapeutics today “Investors following Allergy’s peers will have noted the evolving news this month relating to Stallergenes, which reported a suspension
Allergy Therapeutics PLC (LON:AGY) Tim Higenbottam R&D Director on caught up with DirectorsTalk to discuss the G204 phase 2 study, selection criteria, its comparison to GMM and the phase 3
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today told DirectorsTalk about the enrolment of the first ten US patients in the Company’s GrassMATAMPL (“GMM”) 204 phase
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Allergy Therapeutics
Panmure Gordon Analyst Dr Mike Mitchell said this morning about Allergy Therapeutics (LON:AGY) “This morning Allergy Therapeutics has announced it has completed enrolment with 364 patients in PQBirch204, its phase
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has told DirectorsTalk that it has completed randomisation with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection
Dr Mike Mitchell of Panmure Gordon said this morning about Allergy Therapeutics: “This morning, Allergy Therapeutics has announced a strong trading update for the first four months of 2016 (+12%
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
